Conversely, the low-risk group displayed enrichment in pathways related to immune response and tissue rejection, including the intestinal immune network for IgA production, allograft rejection, graft versus host disease, and proteasome pathways (Figure 7), which suggest that the low-risk patients may have a better immune response, potentially facilitating better control of tumor growth and progression. The gene discussed is CD79A; the disease is graft versus host disease.